Tomatoes Recalled in 14 States as FDA Sets Highest Risk Level
The ongoing recalls, both initiated voluntarily by the distributing firms, involve tomatoes produced by Williams Farms Repack LLC under the brand name Hanshaw & Capling Farm (or H&C Farms) in Immokalee, Florida, and by Ray & Mascari Inc. of Indianapolis.
Newsweek has contacted Ray & Mascari Inc. for comment via email outside regular working hours and Williams Farms Repack LLC via phone.
The recalls affect large quantities of tomatoes distributed across a number of states and include both retail and bulk packaging. The potential contamination with salmonella—a bacteria that can cause serious and sometimes fatal infections in young children, elderly people and those with weakened immune systems—determines the high level of risk to consumers associated with the recall.
Healthy persons infected with salmonella often experience fever, diarrhea (which may be bloody), nausea, vomiting and abdominal pain. In rare circumstances, infection with salmonella can result in the organism getting into the bloodstream and producing more severe illnesses, such as arterial infections (i.e., infected aneurysms), endocarditis and arthritis.
The recall from Williams Farms Repack involves 3,651 boxes of "H&C Farms Raw Premium Tomatoes, Naturally Grown from Seed" packaged in various sizes ranging from jumbo to 6x7, with all requiring refrigeration.
The affected lot is marked as 098 14TO3-1. The product was distributed in Texas, Illinois, Wisconsin, South Carolina, Florida, Tennessee, Indiana and Massachusetts.
The recall was initiated on April 29 and classified by the FDA on May 13.
Separately, Ray & Mascari issued a recall of 510 cases of vine ripe tomatoes. The products were contained in clamshell packages and several bulk packaging sizes. Affected lot numbers range from RM 250420 to RM 250427.
The tomatoes were distributed across Indiana, Kentucky, Massachusetts, Maryland, Michigan, North Carolina, Ohio, Pennsylvania and Wisconsin.
The recall was initiated on April 30 and classified by the FDA on May 13.
While no illnesses have been publicly linked to these products, the Class I designation indicates that use of or exposure to them may cause serious adverse health consequences or death.
The FDA said on its website: "Most people infected with Salmonella will begin to develop symptoms 12 to 72 hours after infection. The illness, salmonellosis, usually lasts four to seven days and most people recover without treatment. Most people with salmonellosis develop diarrhea, fever, and abdominal cramps.
"More severe cases of salmonellosis may include a high fever, aches, headaches, lethargy, a rash, blood in the urine or stool, and in some cases may become fatal. The U.S. Centers for Disease Control and Prevention estimated that approximately 450 persons in the United States die each year from acute salmonellosis.
"Due to the range in severity of illness, people should consult their healthcare provider if they suspect that they have developed symptoms that resemble a Salmonella infection."
Both recalls remain ongoing. Consumers are advised to check for the listed lot numbers and discard any affected products.
Consumers who have purchased the Ray & Mascari products and have questions or reports of any illness may contact the company at 1-317-637-0234 between Monday and Saturday from 6 a.m. to 5 p.m. ET. Consumers who purchased the Williams Farm Repack products may contact the company at 843-866-7707 or 843-599-5154 between Monday and Friday from 8 a.m. to 5 p.m. ET.
Related Articles
Study Reveals Superfood That May Reduce Alzheimer's Risk, Promote LongevityCCTV Captures Dog Seizing His Moment With Tomatoes When Owner 'Not Looking'Tomato Sauce Recall Update as FDA Sets Risk LevelRepublican Suggests Vaccines May Be Getting Injected Into Lettuce
2025 NEWSWEEK DIGITAL LLC.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
FDA Puts Alopecia Treatment on Fast Track
The FDA has granted a 'Fast Track' designation to rezpegaldesleukin (REZPEG) as a treatment for severe-to-very severe alopecia areata, according to a press release from the manufacturer, Nektar Therapeutics. The indication applies to adults and children aged 12 years or older weighing at least 40 kg. REZPEG is a novel biologic that targets 'the interleukin-2 receptor complex in the body to stimulate proliferation of inhibitory immune cells known as regulatory T cells,' according to the company. The Fast Track designation was created to help bring important new treatments to patients as soon as possible and is granted to investigational therapies that may address unmet medical needs for serious conditions, according to the press release. REZPEG is being evaluated in the ongoing Rezolve AA phase 2b study in patients with alopecia areata. In the study, 90 patients with severe-to-very severe alopecia areata (defined as scalp involvement of 50% or more) who were not previously treated with a JAK inhibitor or another biologic were randomized to two different doses of REZPEG or placebo. It will be a self-administered injection, the company said. The primary efficacy endpoint is the mean percent change in the Severity of Alopecia Tool (SALT) score at the end of the 36-week induction period, according to the company. Secondary endpoints include the proportion of participants with reductions in SALT scores of 50% or more at 36 weeks and other timepoints, as well as the mean percent improvement in SALT score at multiple timepoints and the proportion of patients achieving an absolute SALT score ≤ 20. Data from the trial are scheduled to be reported in December 2025, according to the company. The designation follows a previous Fast Track designation for the product as a treatment for moderate-to-severe atopic dermatitis in February.
Medscape
2 hours ago
- Medscape
Empaveli Approved for C3G and Primary IC-MPGN
The FDA has approved pegcetacoplan (Empaveli, Apellis Pharmaceuticals, Inc.) for the treatment of C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients aged 12 years and older. C3G and primary IC-MPGN are rare kidney diseases affecting approximately 5000 people in the US, particularly adolescents or young adults. They often lead to kidney failure requiring dialysis or kidney transplant. In the recently released Phase 3 VALIAN Trial 52-week results, patients receiving pegcetacoplan achieved and maintained a significant reduction in proteinuria over baseline, with a mean urine protein-to-creatinine ratio change at week 26 of -68.1% and at week 52 of -67.2%. In addition, the pegcetacoplan group showed a reduction in estimated glomerular filtration rate levels of -1.2 mL/min/1.73 m2 at week 26 and -3.7 mL/min/1.73 m2 at week 52. The most common adverse reactions were infusion site reactions, pyrexia, nasopharyngitis, influenza, cough, and nausea, according to a company press release. The product will carry a black box warning stating, 'Empaveli, a complement inhibitor, increases the risk of serious infections, especially those caused by encapsulated bacteria, such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B. 'Because of the risk of serious infections caused by encapsulated bacteria, Empaveli is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the EMPAVELI REMS.' Kathleen Dallessio is the Senior Editor for Diabetes & Endocrinology and Nephrology at Medscape Medical News.
Yahoo
3 hours ago
- Yahoo
Press Release: Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment of patients with relapsed or refractory multiple myeloma Paris, July 30, 2025. The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, an IgG1-based Antibody-Dependent Cellular Cytotoxicity-enhanced (ADCC) monoclonal antibody (mAb) targeting G-protein coupled receptor family C group 5 member D (GPRC5D) for the potential treatment of patients with relapsed or refractory multiple myeloma (R/R MM). GPRC5D is highly expressed on plasma cells in MM patients, with low expression in healthy tissues. The FDA grants orphan drug designation to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the US. 'The orphan drug designation is a significant milestone in our ongoing efforts to develop innovative treatments in multiple myeloma,' said , Global Therapeutic Area Head, Immunology and Oncology Development at Sanofi. 'This underscores our commitment to multiple myeloma, a disease for which we have acquired strong expertise with the development of another widely used and approved immunotherapy treatment.' The safety and efficacy of SAR446523 has not been evaluated by any regulatory authority and is still under investigation. About SAR446523SAR446523 is an investigational IgG1-based mAb designed to target GPRC5D, which is highly expressed on plasma cells, with an engineered fragment crystallizable domain to enhance antibody dependent cell-mediated cytotoxicity. This innovative approach aims to improve the efficacy of treatment for MM, a rare and challenging cancer of plasma cells. Subcutaneous SAR446523 is currently being evaluated in an ongoing phase 1, first-in-human study in patients with R/R MM (clinical study identifier: NCT06630806). SAR4465523 originates from Sanofi Research in Vitry-sur-Seine, France. About multiple myelomaMultiple myeloma is considered a rare disease, yet MM is the second most common hematologic malignancy with more than 180,000 people diagnosed with MM each year, globally. Despite available treatments, MM remains an incurable malignancy with an estimated 62% five-year survival rate for newly diagnosed patients. There is a need for new frontline therapeutic options for all patients, especially for those who are transplant ineligible, due to high attrition rates in subsequent lines of therapy. Since MM does not have a cure, most patients will relapse and stop responding to therapies they have received. At Sanofi, we are building on a long-standing commitment to oncology as we continue to chase the miracles of science to improve the lives of those living with cancer. We are committed to transforming cancer care by developing innovative, first and best-in-class immunological and targeted therapies for rare and difficult-to-treat cancers with high unmet need. For more information on MM clinical studies, please visit About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Berland | +1 215 432 0234 | Léo Le Bourhis | +33 6 75 06 43 81 | Victor Rouault | +33 6 70 93 71 40 | Timothy Gilbert | +1 516 521 2929 | Ubaldi | +33 6 30 19 66 46 | Investor RelationsThomas Kudsk Larsen |+44 7545 513 693 | Alizé Kaisserian | +33 6 47 04 12 11 | Lauscher | +1 908 612 7239 | Keita Browne | +1 781 249 1766 | Pham | +33 7 85 93 30 17 | Elgoutni | +1 617 710 3587 | Thibaud Châtelet | +33 6 80 80 89 90 | Yun Li | +33 6 84 00 90 72 | Sanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi Press Release
